GlaxoSmithKline Pharmaceuticals reported a 15.7% year-over-year increase in consolidated net profit for the quarter ended June 30, 2026. Net profit reached ₹237.18 crore for the period. Consolidated revenue from operations totaled ₹938.44 crore. Strong sales in general medicines and vaccines fueled this growth.
The Board of Directors approved the re-appointment of Bhushan Akshikar as Managing Director. His new term will span two years.
GSK is preparing the Indian launch of Blenrep, a treatment for multiple myeloma. The company also received marketing authorization for Arexvy, an RSV vaccine for adults. These upcoming launches are expected to drive future revenue growth.